Evidence map›Paper›PMID 29946777›Full record

ReviewAdvances in experimental medicine and biology

Breast Cancer Metabolism.

Jessica Tan, Anne Le

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessica TanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Anne LeDepartment of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. annele@jhmi.edu.

Funding

Profiling Pancreatic Cancer Metabolism and Tumor Microenvironment for TherapyR21CA169757 · NCI · JOHNS HOPKINS UNIVERSITY · PI LE, ANNE · 2013 to 2014
$382k
NCI NIH HHS R21 CA169757
6 · The paper itself

Abstract

key pointsDespite advances in screening, therapy, and surveillance that have improved survival rates, breast cancer is still the most commonly diagnosed cancer and the second leading cause of cancer mortality among women [1]. Breast cancer is a highly heterogeneous disease rooted in a genetic basis and reflected in clinical behavior. The diversity of breast cancer hormone receptor status and the expression of surface molecules has guided therapy decisions for decades; however, subtype-specific treatment often yields diverse responses due to varying tumor evolution and malignant potential. Although understanding the mechanisms behind breast cancer heterogeneity is still a challenge, available evidence suggests that studying its metabolism has the potential to give valuable insight into the causes of these variations, as well as viable targets for intervention.

Indexed as

AnimalsBreast NeoplasmsFemaleHumansBreast cancerCholine metabolismEstrogen metabolismEstrogen receptor statusGlycolytic upregulationMetabolic fingerprintSerine biosynthesis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.